E. Alvarez-Hornia Pérez , C. Carnelli , P.A. Gutierrez , R. González Sánchez , J. Mesa Quesada
{"title":"Future challenges of contrast media in radiology","authors":"E. Alvarez-Hornia Pérez , C. Carnelli , P.A. Gutierrez , R. González Sánchez , J. Mesa Quesada","doi":"10.1016/j.rxeng.2024.05.004","DOIUrl":null,"url":null,"abstract":"<div><div>Contrast media (CM) were first used soon after the discovery of X-rays in 1895. Ever since, continuous technological development and pharmaceutical research has led to tremendous progress in radiology, more available techniques and contrast media, and expanded knowledge around their indications.</div><div>A greater prevalence of chronic diseases, population ageing, and the rise in diagnosis and survival times among cancer patients have resulted in a growing demand for diagnostic imaging and an increased consumption of CM.</div><div>This article presents the main lines of research in CM development which seek to minimise toxicity and maximise efficacy, opening up new diagnostic and therapeutic possibilities through new molecules or nanomedicine. The sector, which is continuously evolving, faces challenges such as shortages and the need for more equitable and sustainable practices.</div></div>","PeriodicalId":94185,"journal":{"name":"Radiologia","volume":"66 ","pages":"Pages S132-S141"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173510724001320","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Contrast media (CM) were first used soon after the discovery of X-rays in 1895. Ever since, continuous technological development and pharmaceutical research has led to tremendous progress in radiology, more available techniques and contrast media, and expanded knowledge around their indications.
A greater prevalence of chronic diseases, population ageing, and the rise in diagnosis and survival times among cancer patients have resulted in a growing demand for diagnostic imaging and an increased consumption of CM.
This article presents the main lines of research in CM development which seek to minimise toxicity and maximise efficacy, opening up new diagnostic and therapeutic possibilities through new molecules or nanomedicine. The sector, which is continuously evolving, faces challenges such as shortages and the need for more equitable and sustainable practices.
造影剂(CM)是在 1895 年发现 X 射线后不久开始使用的。自那时起,不断的技术发展和药物研究带来了放射学的巨大进步、更多可用的技术和造影剂,以及有关其适应症的更多知识。慢性疾病的流行、人口老龄化以及癌症患者诊断和存活时间的增加导致了对诊断成像的需求不断增长,造影剂的消耗量也随之增加。本文介绍了造影剂开发的主要研究方向,这些方向旨在通过新分子或纳米医学将毒性降至最低并将疗效最大化,从而开辟新的诊断和治疗可能性。该行业在不断发展的同时也面临着各种挑战,如短缺以及需要更加公平和可持续的做法。